GEHC

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

Goldman downgraded GE HealthCare from Buy to Neutral and set a new price target of $65.00

10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

Revenue growth of 7.4%, including Organic revenue growth* of 2.9% Total orders up 1.1% organically versus 10.3% growth in the year-ago period; book-to-bill of 1.07 times and backlog of $21.8 billion Profitability in the quarter was impacted by a discrete PDx supplier issue that has since been resolved Net income margin of 7.6% and Adjusted earnings before interest and taxes (EBIT) margin* of 13.5%; diluted earnings per share (EPS) of $0.85 and Adjusted EPS* of $0.99 Cash flow from operating activities of $290 million and Free cash flow* of $112 million For the full-year 2026, Company reaffirms topline growth driven by healthy global end market demand; reduces profit and Free

GE HealthCare (NASDAQ:GEHC) announced today a strategic evolution to its operations and executive leadership team to help shape the company's next chapter of growth and better serve patients and customers globally. The changes will also position the company to enhance execution, accelerate innovation, and create efficiencies. These changes are effective immediately. Phil Rackliffe has been appointed President and Chief Executive Officer of Advanced Imaging Solutions (AIS), a new segment that combines Imaging and Advanced Visualization Solutions (AVS) to create a $14.6 billion segment.1 This combination brings together GE HealthCare's two largest segments to create a more focused and conne

GE HealthCare (NASDAQ:GEHC) is announcing that members of its management team will present at the following upcoming investor conferences. Bank of America's 2026 Health Care Conference – Tuesday, May 12, 2026 at 10:40 am PT / 1:40 pm ET / 12:40 pm CT Jefferies Global Healthcare Conference – Wednesday June 3, 2026 at 9:20 am ET / 8:20 am CT Webcasts for each event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and soft

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol's clinical development under FDA Fast Track designation The program demonstrates GE HealthCare's commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (NASDAQ:GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic

The expanded collaboration builds on the companies' existing joint initiative by bringing to market enhanced capabilities of DeepHealth's new AI-powered Breast Suite, including ProFound Pro and Safeguard Review GE HealthCare to feature latest technologies to help ensure optimized breast care outcomes across mammography and ultrasound at SBI's 2026 Breast Cancer Imaging Symposium GE HealthCare (NASDAQ:GEHC) today announced an expanded collaboration with DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), to further the innovation, commercialization, and adoption of advanced AI-powered mammography tools. The an

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra

bkActiv provides real-time visualization and now offers digital integration with the Stealth AXiS surgical navigation system, together bringing planning, navigation and robotics into a unified workflow Digital integration designed to help neurosurgeons assess anatomy in real-time and support surgical precision and clinical confidence Collaboration builds on existing strategic alliance between GE HealthCare and Medtronic to accelerate next-generation technology innovation across the enterprise GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which

GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

GE HealthCare Technologies Inc. (NASDAQ:GEHC) (the "Company" or "GE HealthCare") announced today that it received notice on March 30, 2026, of an unsolicited "mini-tender" offer by Potemkin Limited to purchase up to 100,000 shares of GE HealthCare common stock at a price of $45.80 per share in cash. Potemkin Limited's offer price of $45.80 per share is approximately 34.80 percent lower than the $70.25 closing per share price of GE HealthCare's common stock on March 18, 2026, the last trading day before the mini-tender offer appears to have commenced. GE HealthCare does not endorse Potemkin Limited's unsolicited mini-tender offer and recommends that stockholders do not tender their shares

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

COMPASS is one of the largest public‑private partnerships under the European Union's (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (NASDAQ:GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a t

The company will highlight the newly U.S. FDA 510(k) cleared Photonova Spectra photon-counting CT system, ReadyFix fleet management solution enabled to work with MAC VU360 resting ECG workstations, and a new collaboration to advance interventional cardiology At ACC.26, GE HealthCare (NASDAQ:GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout

FDA clearance quickly follows Photonova Spectra's debut at the Radiological Society of North America (RSNA) 2025 Annual Meeting, marking rapid momentum for GE HealthCare's innovative photon-counting CT technology Photonova Spectra introduces the next generation of spectral photon-counting CT technology with 8‑bin energy resolution, powered by GE HealthCare's proprietary Deep Silicon detector technology and a one‑scan universal workflow designed to boost efficiency and reduce complexity across a wide range of CT exams Photonova Spectra is a result of the company's $5.1 billion innovation investment, leading to a wave of transformational products across the portfolio which combined are

DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

3 - GE HealthCare Technologies Inc. (0001932393) (Issuer)